Testing the drug mirdametinib for children and young adults with low-grade glioma
Original title: SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, so it is not care a doctor can give you yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called mirdametinib in young people with a brain tumor called low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary.
Who this trial is for. This trial is for children, teens, and young adults with a low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. It tests a drug called mirdametinib, which can reach the brain.
Where it stands. The trial has not reported results. It is an early study, so the team is looking at how safe the drug is and how it works in young people. That answer is not in yet.
What this means, and what it doesn't
What it could mean: For now, this only means the drug is being tested. Someone who fits the study might ask their care team about it. The care team can say if it makes sense to look into.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help. It is not a cure.
Source: ClinicalTrials.gov, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.